Good clinical practice recommendations for the use of PET/CT in oncology.


Journal

European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988

Informations de publication

Date de publication:
01 2020
Historique:
received: 23 06 2019
accepted: 24 09 2019
pubmed: 23 10 2019
medline: 15 5 2021
entrez: 23 10 2019
Statut: ppublish

Résumé

Positron emission tomography/computed tomography (PET/CT) is a nuclear medicine functional imaging technique with proven clinical value in oncology. PET/CT indications are continually evolving with fresh advances made through research. French practice on the use of PET in oncology was framed in recommendations based on Standards-Options-Recommendations methodology and coordinated by the French federation of Comprehensive Cancer Centres (FNLCC). The recommendations were originally issued in 2002 followed by an update in 2003, but since then, a huge number of scientific papers have been published and new tracers have been licenced for market release. The aim of this work is to bring the 2003 version recommendations up to date. For this purpose, a focus group was set up in collaboration with the French Society for Nuclear Medicine (SFMN) to work on developing good clinical practice recommendations. These good clinical practice recommendations have been awarded joint French National Heath Authority (HAS) and French Cancer Institute (INCa) label status-the stamp of methodological approval. The present document is the outcome of comprehensive literature review and rigorous appraisal by a panel of experts, organ specialists, clinical oncologists, surgeons and imaging specialists. These data were also used for the EANM referral guidelines.

Identifiants

pubmed: 31637482
doi: 10.1007/s00259-019-04553-8
pii: 10.1007/s00259-019-04553-8
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

28-50

Références

Radiat Oncol. 2016 Mar 11;11:37
pubmed: 26968955
Urol Int. 2019;102(1):27-36
pubmed: 30269140
Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):416-27
pubmed: 24258007
Eur Urol Focus. 2018 Sep;4(5):702-706
pubmed: 28753797
J Urol. 2016 May;195(5):1436-1443
pubmed: 26682756
Eur Radiol. 2019 Mar;29(3):1221-1230
pubmed: 30132104
J Clin Oncol. 2002 Jan 15;20(2):379-87
pubmed: 11786564
J Urol. 2019 Apr;201(4):815-820
pubmed: 30672842
Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1410-7
pubmed: 26993315
Eur J Clin Invest. 2019 Mar;49(3):e13063
pubmed: 30580449
Eur J Nucl Med Mol Imaging. 2011 Mar;38(3):426-35
pubmed: 21057787
Prostate Int. 2017 Dec;5(4):125-129
pubmed: 29188197
Eur J Nucl Med Mol Imaging. 2002 Oct;29(10):1317-23
pubmed: 12271413
Eur Urol Focus. 2018 Sep;4(5):686-693
pubmed: 28753806
J Nucl Med. 2018 Jan;59(1):82-88
pubmed: 28646014
Clin Nucl Med. 2016 Jul;41(7):515-21
pubmed: 26975008
Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):678-688
pubmed: 27889802
Cancer Radiother. 2019 Jun;23(3):194-200
pubmed: 31088725
Eur Urol. 2018 Aug;74(2):179-190
pubmed: 29678358
Clin Nucl Med. 2019 May;44(5):365-376
pubmed: 30888999
Eur Urol. 2016 Dec;70(6):926-937
pubmed: 27363387
Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):95-104
pubmed: 30201438
Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):11-20
pubmed: 24072344
Urology. 2019 Mar;125:154-162
pubmed: 30580002
J Nucl Med. 2016 Nov;57(11):1713-1719
pubmed: 27261524
Hell J Nucl Med. 2017 Sep-Dec;20 Suppl:156
pubmed: 29324926
Eur Urol. 2019 Feb 14;:null
pubmed: 30773328

Auteurs

Pierre-Yves Salaün (PY)

Department of Nuclear Medicine, University Hospital of Brest, 5 Avenue Foch, 29609, Brest, France. pierre-yves.salaun@chu-brest.fr.

Ronan Abgral (R)

Department of Nuclear Medicine, University Hospital of Brest, 5 Avenue Foch, 29609, Brest, France.

Olivier Malard (O)

Head and Neck, University Hospital of Nantes, Nantes, France.

Solène Querellou-Lefranc (S)

Department of Nuclear Medicine, University Hospital of Brest, 5 Avenue Foch, 29609, Brest, France.

Gilles Quere (G)

Thoracic Oncology, University Hospital of Brest, Brest, France.

Myriam Wartski (M)

Nuclear Medicine, Cochin Hospital AP-HP, Paris, France.

Romain Coriat (R)

Gastroenterology, Cochin Hospital AP-HP, Paris, France.

Elif Hindie (E)

Nuclear Medicine, University Hospital of Bordeaux, Bordeaux, France.

David Taieb (D)

Nuclear Medicine, AP-HM, Marseille, France.

Antoine Tabarin (A)

Endocrinology, University Hospital of Bordeaux, Bordeaux, France.

Antoine Girard (A)

Nuclear Medicine, Eugène Marquis Center, Rennes, France.

Jean-François Grellier (JF)

Nuclear Medicine, Foch Hospital, Paris, France.

Isabelle Brenot-Rossi (I)

Nuclear Medicine, Paoli-Calmettes Institute, Marseille, France.

David Groheux (D)

Nuclear Medicine, Hopital Saint Louis AP-HP, Paris, France.

Caroline Rousseau (C)

Nuclear Medicine, Ouest Cancer Institute, Nantes, France.

Désirée Deandreis (D)

Nuclear Medicine, Department of Medical Sciences, Citta della Salute e della Scienza, Turin, Italy.

Jean-Louis Alberini (JL)

Nuclear Medicine, Georges-François Leclerc center - François Mitterrand University Hospital, Dijon, France.

Caroline Bodet-Milin (C)

Nuclear Medicine, University Hospital of Nantes, Nantes, France.

Emmanuel Itti (E)

Nuclear Medicine, Henri Mondor Hospital AP-HP, Paris, France.

Olivier Casasnovas (O)

Hematology, University Hospital Le Bocage, Dijon, France.

Françoise Kraeber-Bodere (F)

Nuclear Medicine, Ouest Cancer Institute, Nantes, France.
Nuclear Medicine, University Hospital of Nantes, Nantes, France.

Philippe Moreau (P)

Hematology, University Hospital of Nantes, Nantes, France.

Arnaud Philip (A)

Centre du traitement de la douleur, CHRU de Brest, Brest, France.

Corinne Balleyguier (C)

Radiology, Gustave Roussy Institute, Villejuif, France.

Alain Luciani (A)

Radiology, Henri Mondor Hospital AP-HP, Paris, France.

Florent Cachin (F)

Nuclear Medicine, Jean Perrin Cancer Institute, Clermont-Ferrand, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH